UBS analyst Danielle Antalffy initiated coverage of AtriCure with a Buy rating and $56 price target. The analyst expects the company to grow sales at 17% annually through 2025 as new products’ ease of use, efficiency, and clinical outcomes encourage procedural growth and adoption. The firm’s sales estimates are 2% above the Street in both 2024 and 2025, driven by higher Appendage Management and Pain Management estimates. It says AtriCure trades at a discount to its SMID-cap peers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
